The estimated Net Worth of Andrew J. Last is at least $355 Tisíc dollars as of 17 August 2022. Andrew Last owns over 20,000 units of Oncocyte stock worth over $217,527 and over the last 9 years he sold OCX stock worth over $0. In addition, he makes $137,841 as Independent Director at Oncocyte.
Andrew has made over 6 trades of the Oncocyte stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of OCX stock worth $17,400 on 17 August 2022.
The largest trade he's ever made was buying 20,000 units of Oncocyte stock on 17 August 2022 worth over $17,400. On average, Andrew trades about 1,810 units every 87 days since 2016. As of 17 August 2022 he still owns at least 70,170 units of Oncocyte stock.
You can see the complete history of Andrew Last stock trades at the bottom of the page.
Dr. Andrew J. Last serves as Independent Director of the Company. In April 2019, Dr. Last was appointed as Executive Vice President and Chief Operating Officer of Bio-Rad Laboratories, Inc. Dr. Last previously served as Chief Commercial Officer at Berkeley Lights Inc. and as Chief Operating Officer of Intrexon Corporation. From 2010 to 2016, Dr. Last was Executive Vice President and Chief Operating Officer of Affymetrix. Before joining Affymetrix, Dr. Last served as Vice President, Global and Strategic Marketing of BD Biosciences and as General Manager of Pharmingen from 2004 to 2010. From 2002 to 2004, Dr. Last held management positions at Applied Biosystems, Inc., including as Vice President and General Manager from 2003-2004 and Vice President of Marketing 2002-2003. Earlier in his career, he served in a variety of management positions at other companies, including Incyte Genomics and Monsanto. Dr. Last holds Ph.D. and MS degrees with specialization in Agrochemical Chemicals and Bio-Aeronautics, respectively, from Cranfield University, and a BS degree in Biological Sciences from the University of Leicester in the United Kingdom.
As the Independent Director of Oncocyte, the total compensation of Andrew Last at Oncocyte is $137,841. There are 5 executives at Oncocyte getting paid more, with Ronald Andrews having the highest compensation of $2,102,210.
Andrew Last is 60, he's been the Independent Director of Oncocyte since 2015. There are 5 older and 2 younger executives at Oncocyte. The oldest executive at Oncocyte Corporation is Dr. Michael D. West Ph.D., 68, who is the Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc..
Andrew's mailing address filed with the SEC is C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE, CA, 92618.
Over the last 9 years, insiders at Oncocyte have traded over $16,389,842 worth of Oncocyte stock and bought 56,056,405 units worth $102,313,246 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Cell Therapeutics, Inc. Lin... a Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of $3,382,106. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth $10,001.
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
Oncocyte executives and other stock owners filed with the SEC include: